Navigation Links
Stem cell mobilization therapy found to be safe for bone marrow donors
Date:8/11/2011

(WASHINGTON, August 11, 2011) According to a study published in Blood, the Journal of the American Society of Hematology (ASH), researchers have reported that administration of granulocyte colony-stimulating factor (G-CSF), a drug that releases stem cells from the bone marrow into the blood, is unlikely to put healthy stem cell donors at risk for later development of abnormalities involving loss or gains of chromosomes that have been linked to hematologic disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

G-CSF therapy is given to healthy stem cell donors in order to move the donor's stem cells out of the bone marrow and into the blood stream, a process called mobilization. Once in the blood, large doses of stem cells can be collected safely and without surgery via a process called apheresis, avoiding bone marrow harvest in the operating room. Research has shown that the large doses of mobilized stem cells (called peripheral blood stem cells or PBSCs) can repopulate the bone marrow and create new blood cells faster than stem cells collected directly from the bone marrow, and a number of long-term follow-up studies have demonstrated that healthy donors are not at an increased risk of developing leukemia or other cancers following PBSC donation.

"In recent years, PBSCs have become the dominant source of stem cells for stem cell transplants and the number of transplants performed with PBSCs that have been mobilized with G-CSF has substantially increased. However, the potential for the therapy to cause DNA damage, mutations, or cancer had been suggested in a smaller and less comprehensive prior study, raising a serious concern within the transplant community and making a definitive study very important. Our study aimed at investigating potential effects of G-CSF on chromosomes in healthy donors," said Betsy Hirsch, PhD, first author of the study and Associate Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota Medical School.

In order to explore whether G-CSF therapy is indeed a potential cause of chromosome loss or gain in donors, a research team from the University of Minnesota Medical School conducted a study to determine whether there was any risk with short-term, low-dose usage of G-CSF on healthy PBSC donors. The study evaluated blood samples taken from 22 PBSC donors who had received G-CSF and 22 controls with no history of cancer or prior exposure to the therapy over a 12 month period.

Using fluorescence in situ hybridization (FISH), a technique that can detect specific targeted regions of DNA in an individual's cells to identify chromosomal abnormalities, the researchers evaluated the white blood cells of the study subjects for aneuploidy, a condition in which there is an abnormal number of chromosomes. Loss and gain of chromosomes represent one form of chromosome instability that is frequently a step in the development of cancer. Specifically, the researchers focused on chromosome 7 and a series of other chromosomal regions well documented to be associated with MDS and AML. The researchers also evaluated the cells to determine if both copies of a given chromosome replicated in synchrony or asynchronously, as asynchronous replication can also signal genomic instability and a higher risk of chromosomal abnormalities.

"Contrary to the previously published data, our study concludes that G-CSF stimulation does not result in replication asynchrony or induce the atypical levels of abnormality for chromosome 7 or other chromosomes that have been associated with MDS and AML, and we expect that these results can be generalized to all chromosomes," said Dr. Hirsch.

Jeffrey McCullough, MD, senior study author and Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota Medical School, added, "Furthermore, our data support the conclusion that G-CSF does not induce chromosomal instability through the PBSC mobilization process and remains a safe therapy for healthy stem cell donors."


'/>"/>

Contact: Lindsey Love
webmaster@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. CPAP Therapy Most Effective for Sleep Apnea, Experts Say
2. Hormone reduces risk of heart failure from chemotherapy
3. Stem Cell Therapy Holds Promise for Kidney Disease
4. Aggressive drug therapy aids superbug evolution
5. Combination of existing safety checks could greatly reduce radiotherapy errors
6. New therapy may help people with unexplained symptoms of pain, weakness and fatigue
7. Scientists developing new therapy for HER2-positive breast cancer
8. Hormone therapy may be hazardous for men with heart conditions
9. Penn receives $10 million to create center for orphan disease research and therapy
10. BUSM: Testosterone deficiency and replacement therapy in men
11. International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SC&H Group, ... firm as a Principal in its IT Advisory Services practice . Rossi is ... months as market demand for strategic IT guidance grows, and the practice continues to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education ... Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on ... announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra Lee ...
(Date:1/17/2017)... ... January 17, 2017 , ... Many people make New Year’s resolutions or renew their commitment to ... making it easier for people who want to kick off 2017 with better smiles. Dr. ... , These special offers include: , , A new patient ...
(Date:1/16/2017)... ... January 17, 2017 , ... ... an internationally recognized leader in the fast-casual category, announces a hearty and wholesome ... Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow ...
(Date:1/16/2017)... ... 16, 2017 , ... Gym Source, America’s leading retailer of premium residential and ... New Jersey. , “We are elated to be opening this new showroom,” explains Tom ... to give clients a seamless and motivating shopping experience.” , Every fitness journey is ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... in a Phase 3 clinical trial comparing the efficacy ... in the prevention of hepatic veno-occlusive disease (VOD) in ... (HSCT) who are at high risk or at very ... will be conducted across approximately 100 medical centers in ...
(Date:1/17/2017)... According to a new market research report "Neural Network Software Market by Type (Data ... - Global Forecast to 2021" published by MarketsandMarkets, the market to expand from ... Compound Annual Growth Rate (CAGR) of 33.2%. Continue ... ... ...
(Date:1/17/2017)...  OrthoAccel ® Technologies, Inc. announces that the ... "The Effect of Vibration on Molar Distalization," a study ... S. Jay Bowman , this prospective, peer-reviewed clinical study ... Technology ® speeds up molar distalization rates in ... of days to move the upper molars into a ...
Breaking Medicine Technology: